Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE.

Nicholas David James, Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, Ann Pope, Darren Barton, Adam Daunton, Duncan McLaren, Joe M. O'Sullivan, Chris Parker, John Staffurth, Andrew Stanley, James Wylie, Sharon Beesley, Alison J. Birtle, Janet Elizabeth Brown, Prabir R. Chakraborti, John Martin Russell, Lucinda Billingham

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Volume33
Issue number15
DOIs
Publication statusPublished - 20 May 2015
EventAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer - Chicago, Israel
Duration: 29 May 20152 Jun 2015

Cite this